Community Practice Connections™: Melanoma Tumor Board: Matching Treatment to Patient

Community Practice Connections™: Melanoma Tumor Board: Matching Treatment to Patient is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with melanoma. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of melanoma may also participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
The management of melanoma has shifted in recent years, with improved understanding of signaling pathways and resistance mechanisms underlying the pathogenesis of metastatic melanoma. This has led to advances in the development of targeted therapies. These new approaches have given physicians the ability to target previously unreachable treatment goals to improve patient outcomes. Novel treatment strategies for advanced melanoma raise challenging questions, and uncertainty often arises regarding the best strategies for integrating new treatments into current treatment paradigms, in addition to concerns for the proactive management of treatment-related adverse events.

The ability to evaluate efficacy of new therapies, manage adverse events, and implement biomarkers for selecting therapy is critical for making informed decisions and optimizing patient care. This educational activity is based on a live symposium held adjunct to the 2019 clinical oncology annual meeting in Chicago. Through a series of written passages and brief video interviews, expert faculty review the impact of clinical data on patient care, discuss clinical cases, and share forward-looking perspectives on the treatment of advanced melanoma.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Assess recently reported clinical trial data for safety and efficacy of emerging therapies, novel combinations, and therapeutic sequencing strategies for melanoma treatment
• Apply best practices to proactively identify and mitigate the impact of treatment-related toxicities in settings where patients with melanoma are managed
• Discuss emerging data on the use of biomarkers to guide individualized care for patients with melanoma
• Integrate emerging data on therapeutic sequencing options into the context of treatment for patients with melanoma

Additional details will be posted as soon as information is available.